Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29047018 | 0.97 | PREP (0.38) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31634841 | 0.97 | PREP (0.38) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14962495 | 0.92 | PREP (0.39) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29000115 | 0.91 | PREP (0.40) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL24436816 | 0.88 | PREP (0.41) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19605886 | 0.88 | KDM4E (0.36) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27437851 | 0.88 | PREP (0.33) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL24436825 | 0.88 | PREP (0.41) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10261302 | 0.87 | KDM4E (0.38) | PREPCELA1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL9135689 | 0.87 | PREP (0.44) | PREPCELA1ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707819-A | Preparation method of pyrazolone amino acid ester derivative | 福建师范大学 | 2025-03-28 | — | — | CN | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| WO-2022163846-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | 第一三共株式会社 | 2022-08-04 | — | — | WO | claimed |
| CN-111978362-A | Method for removing isocoryzanol in natural product hesperidin | 崔仁发 | 2020-11-24 | — | — | CN | claimed |
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-1051506-B2 | PROCEDURES FOR THE EXTRACTION AND ISOLATION OF BACTERIAL CAPSULAR POLYSACCHARIDES FOR USE AS VACCINES OR LINKED TO PROTEINS AS CONJUGATES VACCINES | PFIZER IRELAND PHARMACEUTICALS (IE) | 2019-08-21 | — | — | EP | claimed |
| CN-1653642-A | Non-aqueous electrolyte solution and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2005-08-10 | — | — | CN | claimed |
| EP-1498978-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | Ube Industries, Ltd. (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20010051364-A1 | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines | MICHON FRANCIS (US) | 2001-12-13 | — | — | US | claimed |
| US-6248570-B1 | SIMPLE, EFFICIENT, NONFLAMMABLE METHOD BY CONTACTING CELLULAR COMPONENTS WITH BASE TO FORM MIXTURE OF PH 9 TO 14, SEPARATING CAPSULAR POLYSACCHARIDES FROM OTHER CELLUAR COMPONENTS, THEN RECOVERING CAPSULAR POLYSACCHARIDES | BAXTER INTERNATIONAL, INC. | 2001-06-19 | — | — | US | claimed |
| EP-1051506-A1 | PROCEDURES FOR THE EXTRACTION AND ISOLATION OF BACTERIAL CAPSULAR POLYSACCHARIDES FOR USE AS VACCINES OR LINKED TO PROTEINS AS CONJUGATES VACCINES | NORTH AMERICAN VACCINE, INC. (CA) | 2000-11-15 | — | — | EP | claimed |
| WO-1999032653-A9 | PROCEDURES FOR THE EXTRACTION AND ISOLATION OF BACTERIAL CAPSULAR POLYSACCHARIDES FOR USE AS VACCINES OR LINKED TO PROTEINS AS CONJUGATES VACCINES | NORTH AMERICAN VACCINE INC (US) | 1999-10-28 | — | — | WO | claimed |
| WO-1999032653-A1 | PROCEDURES FOR THE EXTRACTION AND ISOLATION OF BACTERIAL CAPSULAR POLYSACCHARIDES FOR USE AS VACCINES OR LINKED TO PROTEINS AS CONJUGATES VACCINES | NORTH AMERICAN VACCINE, INC. (US) | 1999-07-01 | — | — | WO | claimed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1998043936-A2 | IMPROVED METHODS OF MANUFACTURING BETULINIC ACID | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1998-10-08 | — | — | WO | claimed |
| US-5804575-A | Methods of manufacturing betulinic acid | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1998-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | PREP 2897/4885CELA1 2986/4885ALDH1A1 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.